CurrentBlue Cross Blue Shield - MassachusettsPolicy 801

Surgical deactivation of headache trigger sites

This Blue Cross Blue Shield Massachusetts medical policy (Policy 801 / BCBSA Ref 7.01.135) addresses surgical deactivation of trigger sites for treatment of migraine and non-migraine headaches, defining coverage stance across commercial and Medicare products and authorization requirements.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicySurgical deactivation of headache trigger sites

Policy CodePolicy 801

Change TypeLiterature review (no change)

Effective Date

Next Review Date

Key ActionPrecertification/preauthorization is required for all products if surgical deactivation is performed inpatient.

SourceLink

POLICY UPDATE CHANGES

Policy updated with literature review through January 2, 2026; no references added. Policy statements unchanged.

Annual policy review entries for prior years listed; policy statements unchanged.

Original policy established as investigational in 2/2013.

1Coverage stance (Investigational)

0Covered outpatient settings

1Inpatient preauthorization required

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Surgical deactivation of headache trigger sites is a set of operative procedures developed to treat migraine by removing or decompressing portions of nerves, surrounding musculature, fascia, or vessels at identified trigger sites (frontal, temporal, rhinogenic, occipital). Techniques vary by site and may include muscle removal, nerve segment excision, septoplasty/turbinectomy, or insertion of protective flaps; procedures are typically performed under general anesthesia in an ambulatory setting and take about an hour.

The intended indications include treatment of migraine headaches and, based on proposed shared pathophysiology, have also been proposed for some non-migraine headaches (eg, tension-type or rhinogenic headaches) where trigeminal/occipital nerve irritation is suspected.

High-level coverage stance: surgical deactivation of trigger sites is considered INVESTIGATIONAL and is not a covered outpatient service across the listed commercial and Medicare product types; the policy has been maintained as investigational through periodic literature reviews (most recently updated through January 2, 2026).

Policy identifiers and status

policy_number801

dates.last_review2026-02-01

statusCURRENT / Investigational

scope_summaryBCBSA Policy 801 (Ref 7.01.135): surgical deactivation of headache trigger sites for treatment of migraine and non-migraine headaches; defines coverage stance across commercial and Medicare products and authorization requirements

Coverage determination

Policy statement:

Surgical deactivation of trigger sites is considered INVESTIGATIONAL for the treatment of migraine and non-migraine headache.
Commercial Managed Care (HMO and POS), Outpatient: This is not a covered service.
Commercial PPO and Indemnity, Outpatient: This is not a covered service.
Medicare HMO Blue, Outpatient: This is not a covered service.
Medicare PPO Blue, Outpatient: This is not a covered service.

Authorization requirements

Facility-level authorization rules for site of service:

For services described in this policy, precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient.
For services described in this policy, prior authorization might be required for some products if the procedure is performed outpatient (check product-specific rules).

Provider Actions

Prior Authorization

Inpatient preauthorization required

Precertification/preauthorization is required for all products when the surgical deactivation procedure is performed in the inpatient setting.

Applies to all products when procedure is performed inpatient.

Prior Authorization

Outpatient prior authorization may be required

Prior authorization may be required for some products when the surgical deactivation procedure is performed in the outpatient setting; providers must check product-specific outpatient authorization rules before scheduling.

Verify product-specific outpatient prior-authorization rules before scheduling the procedure.

Documentation Required

Report services with appropriate codes

Report all services using current industry-standard procedure, revenue, and diagnosis codes, and include applicable modifiers; note that there is no specific CPT code for this service.

Use the most up-to-date procedure, revenue, and diagnosis codes.
Include applicable modifiers where relevant.
Be aware: there is no specific CPT code for this service.

Coding

CPT codesCPT

none	There is no specific CPT code for this service.

References / NCD/LCDmixed

N/A	NCD/LCD: N/A

There is no specific CPT code for surgical deactivation of trigger sites; providers should report services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable. Precertification/preauthorization rules apply as noted in the policy and providers should verify product-specific authorization requirements before scheduling services.

Background & Evidence Summary

Surgical deactivation involves identifying patient-specific migraine trigger sites and surgically treating those sites by removing or decompressing nerve segments, adjacent muscles, fascia, or vessels believed to irritate trigeminal or occipital nerve branches; the technique was developed after observations of migraine improvement following cosmetic forehead lifts and is based on the theory that local irritation causes inflammation of trigeminal/occipital nerve branches leading to headaches.

Randomized controlled trials: Three RCTs have been published evaluating surgical deactivation for migraine; only one trial used a sham control with patient blinding. While all three reported statistically significant better outcomes at 12 months for decompression surgery versus control, the trials had methodological limitations (including unclear/variable patient selection and variability in procedures by trigger site) and two unblinded trials are susceptible to placebo effects, leaving evidence insufficient to establish net health benefit.

Non-migraine headache evidence: There are no published studies of surgical deactivation for non-migraine headaches; therefore evidence is insufficient to determine benefit for non-migraine headache indications.

Key conclusions

Policy conclusionInvestigational; insufficient evidence to determine net health outcome

RCTs identifiedThree (one sham-controlled)

Surgical deactivation of trigger sites: Surgical procedures (frontal, temporal, rhinogenic, occipital) to remove or decompress nerve segments, surrounding muscles, fascia, or vessels believed to trigger headaches.

Revision History

2026-02-01revisedLatest

Policy updated with literature review through January 2, 2026; no references added. Policy statements unchanged.

2025-04-01revised

Annual policy review. References updated. Policy statements unchanged.

2024-04-01revised